Key result
Carotid intima-media thickness (CIMT) is consistently related to future cardiovascular events and its progression is reduced by lipid- and blood pressure-lowering therapies.
Why the study?
Does the measurement of carotid intima-media thickness (CIMT) serve as a valid surrogate marker for cardiovascular disease in intervention studies?
Population
Patients at risk for cardiovascular disease in intervention studies
Design
Review
Authors
Loading...
Supports CIMT as surrogate in CV trials; leaves open whether measurement should guide individual management.
Does the measurement of carotid intima-media thickness (CIMT) serve as a valid surrogate marker for cardiovascular disease in intervention studies?
CIMT is a safe, highly reproducible surrogate marker for atherosclerosis and cardiovascular risk that can provide earlier indications of efficacy in clinical trials.
Michiel L. Bots (2006) conducted a review in Cardiovascular disease. Carotid intima-media thickness (CIMT) was evaluated on Cardiovascular disease events. Carotid intima-media thickness (CIMT) is consistently related to future cardiovascular events and its progression is reduced by lipid- and blood pressure-lowering therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: